Market News Comments

Pfizer (PFE)

Pfizer announced that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company`s candidate 13-valent pneumococcal conjugate vaccine.
As a result, the review will continue beyond the prescription drug user fee (PDUFA) action date of December 30, 2009.

Dec 31 · 1:38:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Enter your comment below and click Submit:

Copyright © 2010 MarketBeast.com.
All rights reserved.